Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 13, 2017 (10 years ago)

Duopa (carbidopa and levodopa enteral suspension)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Stability Specifications: confirmed out of specification results obtained during refrigerated material stability testing indicating that drug may settle within drug cassettes nearing the end of their refrigerated shelf-life

Cause type: Stability / shelf life

The product degraded or failed stability testing before its labeled expiry. Heat, moisture or time can break the drug down into degradants or reduce potency. All stability / shelf life recalls.

What was recalled

Duopa (carbidopa and levodopa enteral suspension), 4.63 mg/20 mg per mL, 100 mL cassette, 7 cassettes per carton, Rx Only, AbbVie Inc., North Chicago, IL 60064 --- NDC 0074-3012-07

Affected NDC 0074-3012-07

Compare with the code on your package — it is the most precise check available.

Drug: Levodopa

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Duopa
Carbidopa and Levodopa
NDC 00074-3012
LEVODOPA 20 mg/mL; CARBIDOPA HYDRATE 4.63 mg/mL Suspension
Enteral
AbbVie Inc. Rx
Recalling firm
AbbVie Inc.
NDC code
0074-3012-07
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0495-2017 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Levodopa recalls

See all
Class II · Moderate risk

Carbidopa

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

Ongoing Labeling / mix-up Rising Pharma Holding, Inc. NDC 16571-691-01 D-0029-2026
Class II · Moderate risk

Carbidopa and Levodopa Tablets

Packaging defect: observed packaging defect, blister packaging inadequately sealed.

Terminated Packaging defect The Harvard Drug Group NDC 0904-7257-61 D-0432-2023
Class II · Moderate risk

Levodopa 250 mg NSR Capsules

Lack of Assurance of Sterility and Stability Data does not Support Expiry: recent inspection observations associated with certain quality control procedures that present a risk to sterility and quality assurance.

Terminated Sterility / contamination Health Innovations Pharmacy, Inc D-1036-2015

Other recalls by AbbVie Inc.

All 2017 recalls
Class II · Moderate risk

Refresh P.M.

Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.

Ongoing Sterility / contamination AbbVie Inc. D-0664-2024
Class III · Low risk

Synthroid

Labeling: Wrong Barcode- One (1) of every forty (40) unit dose blister will contain incorrect barcode information that causes a 125mcg unit dose is scanned as 200mcg unit dose.

Ongoing Labeling / mix-up AbbVie Inc. NDC 0074-7068-11 D-0088-2024